# Study of SHR-A1921 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors

> **NCT05765032** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Suzhou Suncadia Biopharmaceuticals Co., Ltd.** · enrollment: 220 (actual)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** SHR-A1921；

## Key facts

- **NCT ID:** NCT05765032
- **Lead sponsor:** Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-12-30
- **Primary completion:** 2025-04-30
- **Final completion:** 2026-02-28
- **Target enrollment:** 220 (ACTUAL)
- **Last updated:** 2024-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05765032

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05765032, "Study of SHR-A1921 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05765032. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*